ArticleBiomarker research2026

Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer.

Marta Molina-Alejandre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.